Accès gratuit
Numéro
Med Sci (Paris)
Volume 23, Numéro 5, Mai 2007
Page(s) 502 - 508
Section M/S revues
DOI https://doi.org/10.1051/medsci/2007235502
Publié en ligne 15 mai 2007
  1. Karre K, Ljunggren HG, Piontek G, et al. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 1986; 319 : 675–8.
  2. Ahmad A, Alvarez F. Role of NK and NKT cells in the immunopathogenesis of HCV-induced hepatitis. J Leuk Biol 2004; 76 : 743–59.
  3. Lanier LL. NK Cell Recognition. Annu Rev Immunol 2005; 23 : 225–74.
  4. Katz G, Gazit R, Arnon T, et al. MHC class I independent recognition of NK activating receptor KIR2DS4. J Immunol 2004; 173 : 1819–25.
  5. Ruggeri L, Capanni M, Casucci M, et al. Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation. Blood 1999; 94 : 333–9.
  6. Ruggeri L, Capanni M, Urbani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002; 295 : 2097–100.
  7. Giebel S, Locatelli F, Lamparelli T, et al. Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors. Blood 2003; 102 : 814–9.
  8. Ruggeri L, Mancusi A, Capanni M, et al. Exploitation of alloreactive NK cells in adoptive immunotherapy of cancer. Curr Opin Immunol 2005; 17 : 211–7.
  9. Cudkowicz G, Bennett M. Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice. J Exp Med 1971; 135 : 1513–28.
  10. Ogasawara K, Benjamin J, Takai R, et al. A role for NKG2D in NK cell-mediated rejection of mouse bone marrow grafts. Nat Immunol 2005; 6 : 938–45.
  11. Lundqvist A, McCoy JP, Samsel L, et al. Reduction of GvHD and enhanced anti-tumor effects after adoptive infusion of alloreactive Ly49-mismatched NK-cells from MHC-matched donors. Blood 2007; 109 : 3603–6.
  12. Coupel S, Moreau N, Hamidou M, et al. Expression and release of soluble HLA-E is an immunoregulatory feature of endothelial cell activation. Blood 2006; online 19 décembre.
  13. Chan GW, Gorgun G, Miller KB, Foss FM. Persistence of host dendritic cells after transplantation is associated with graft versus host disease. Biol Blood Marrow Transpl 2003; 9 : 170–6.
  14. Barber DF, Faure M, Long EO. LFA-1 contributes an early signal for NK cell cytotoxicity. J Immunol 2004; 173 : 3653–9.
  15. Caligiuri MA, Velardi A, Scheinberg DA, et al. Immunotherapeutic approaches for hematologic malignancies. Hematology 2004; 337–53.
  16. Hsu KC, Keever-Taylor CA, Wilton A, et al. Improved outcome in HLA-identical sibling hematopoietic stem cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes. Blood 2005; 105 : 4878–84.
  17. Schaffer M, Malmberg KT, Ringden O, et al. Increased infection-related mortality in KIR ligand mismatched unrelated allogeneic transplantation in AML. Transplantation 2004; 78 : 1081–5.
  18. Davies SM, Ruggieri L, DeFor T, et al. Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Blood 2002; 100 : 3825–7.
  19. Giebel S, Nowak I, Wojnar J, et al. Impact of activating killer immunoglobulin-like receptor genotype on outcome of unrelated donor-hematopoietic cell transplantation. Transplant Proc 2006; 38 : 287–91.
  20. Verheyden S, Scots S, Duguet W, Demanet C. A defined donor activating natural killer cell receptor genotype protects against leukemia relapses after related identical hematopoietic stem cell transplantation. Leukemia 2005; 19 : 1446–51.
  21. Kroger N, Binder T, Zabelina T, et al. Low number of donor activating killer immunoglobulin-like receptor (KIR) genes but not KIR-ligand mismatch prevents relapses and improves disease-free survival in leukemia patients after in vivo T cell-depleted unrelated stem cell transplantation. Transplantation 2006; 82 : 1024–30.
  22. Albertsson PA, Basse PH, Hokland M, et al. NK cells and the tumour microenvironment: implications for NK-cell function and anti-tumour activity. Trends Immunol 2003; 24 : 603–9.
  23. Ishigami S, Natsugoe S, Tokuda K, et al. Prognostic value of intratumoral natural killer cells in gastric carcinoma. Cancer 2000; 88 : 577–83.
  24. Lee SG, Heo DS, Yoon S, et al. Effect of GM-CSF and IL-2 co-expression on anti-tumor immune response. Anticancer Res 2000; 20 : 2681–6.
  25. Son YI, Dallal RM, Mailliard RB, et al. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res 2001; 61 : 884–8.
  26. Salih HR, Antropius A, Gieseke F, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003; 102 : 1389–96.
  27. Fauriat C, Just-Landi S, Mallet F. Deficient expression of NCR in NK cells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemic cells in NCR dull phenotype induction. Blood 2007; 109 : 323–30.
  28. Demanet C, Moulder A, Denevers A. Downregulation of HLA-A and HLA-Bw6, but not HLA-Bw4 allospecificities, in leukemia cells: an escape mechanism from CTL and NK attack ? Blood 2004; 15 : 3122–30.
  29. Bukur J, Rebmann V, Gross-Wilde H, et al. Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma. Cancer Res 2003; 63 : 4107–11.
  30. Tripathy P, Agarwal S. Non classical HLA-G antigen and its role in the cancer progression. Cancer Invest 2006; 24 : 178–86.
  31. Imai C, Iwamoto S, Campana D. Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells. Blood 2005; 106 : 376–83.
  32. Koh CY, Blazar BR, George T, et al. Augmentation of antitumor effects by NK cell inhibitory receptor blockade in vitro and in vivo. Blood 2001; 97 : 3132–7.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.